Most recent update: Friday, January 24, 2020 - 11:27

Bariatric News - Cookies & privacy policy

You are here


Status of bariatric and metabolic surgery in Korea

A survey reporting the current status of bariatric and metabolic operations in South Korea has reported that the increase in the numbers of sleeve gastrectomies (SG) and RYGBs in Korea mirror those of worldwide trends. However, unlike the rest of the world, the adjustable gastric band (AGB) were reported to have the largest increase and was the most common bariatric and metabolic procedure.

Bypass better banding for T2DM treatment

Roux-en-Y gastric bypass surgery resulted in the greatest average weight loss and appears to be the best treatment for T2DM compared to gastric banding and lifestyle intervention, according to a paper 'Surgical vs Medical Treatments for Type 2 Diabetes Mellitus - A Randomized Clinical Trial' published in JAMA Surgery. The outcomes from this clinical trial also highlighted several challenges of completing a larger trial with patients with a BMI>30-40.

STAMPEDE: 3 year results show surgical effectiveness

Three year outcomes from the Surgical Therapy And Medications Potentially Eradicate Diabetes Efficiently (STAMPEDE) trial has shown that bariatric surgery is a highly effective and durable treatment for type 2 diabetes in obese patients, enabling nearly all surgical patients to be free of insulin and many to be free of all diabetic medications three years after surgery.

BioKier to use Phloral technology for bypass mimicking drug

BioKier has signed an exclusive global license with UCL Business for colonic delivery of gut hormone secretagogues for treatment of metabolic diseases. including diabetes. The proprietary colon delivery technology, Phloral, developed by researchers at the UCL School of Pharmacy, will be used in the formulation of an anti-diabetes drug, BKR-013, under development by BioKier. 

Ten-year trial: bypass beats band

A trial designed to assess outcomes for patients receiving laparoscopic adjustable gastric banding (LAGB) vs. laparoscopic Roux–en-Y gastric bypass (LRYGB) has reported bypass has better weight loss and reduced number of failures, despite significantly longer operative time and life-threatening complications.

Bypass surgery reduces risk of heart attack

Gastric bypass surgery can lead to significantly reduced cardiac risk factors even seven years after the operation, according to new research presented at the ASMBS’ 29th annual meeting in San Diego.

The study, ‘Long Term Improvement in Biochemical Cardiac Risk Factors Following Gastric Bypass’, found that 11 risk factors for heart attack, including total cholesterol, triglycerides and C-reactive protein levels, remained greatly reduced in patients during long-term follow-up.

Subscribe to RSS - bypass